- Therma Bright (THRM) receives patent from the U.S. Patent & Trademark Office (USPTO)
- The patent is for a device that can apply heat and antimicrobial treatment through a detachable copper or silver applicator
- The heat and antimicrobial treatment technology is combined as the solution for the prevention of cold sores
- Therma Bright is currently undergoing design upgrades to both devices and expects to complete prototyping during Q2
- Therma Bright Inc. (THRM) is in the grey, trading at C$0.26 at 1:23 pm EST
Therma Bright Inc. (THRM) has received a patent from the U.S. Patent and Trademark Office.
The patent is for a device that can apply heat and antimicrobial treatment through a detachable applicator comprising copper or silver to provide heat conductivity and an antimicrobial agent.
The device also includes a light source. This U.S. patent applies to both Therma Bright’s InterceptCS™ Cold Sore Prevention Device and TherOZap™ Insect Bite Relief Device.
Specific to the InterceptCS™ device, this heat and antimicrobial treatment technology is combined as the solution for the prevention of cold sores.
As for the TherOZap™ device, the treatment technology aims to reduce the inflammatory response, relieving the symptoms of pain, itch and inflammation associated with insect bites and stings.
Furthermore, as shared in earlier press releases, the company engaged a top Virology Research Laboratory in Canada to study the TherOZap™ technology’s ability to inactivate live Zika virus in culture media and that the TherOZap™, which utilizes specialized materials, coatings and heat, was able to limit Zika virus (“ZIKV”) replication in cell cultures.
“This is exciting news for Therma Bright and our TherOZap™ Insect Relief Device and InterceptCS™ Cold Sore Prevention Device,” shared Rob Fia, CEO of Therma Bright.
“This allowed U.S. Patent Application further protects our valued intellectual property (IP) as we continue to transform innovation into wellness,” added Fia.
Therma Bright is currently undergoing design upgrades to both devices and expects to complete prototyping during Q2.
In addition, it plans to continue its research with the new TherOZap™ design on Zika and other mosquito-borne diseases during 2022.
Therma Bright, the developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today’s most important medical and healthcare challenges.
The Company’s initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare.
Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings.
Therma Bright Inc. (THRM) is in the grey, trading at C$0.26 at 1:23 pm EST.